Cullinan Therapeutics (NASDAQ:CGEM) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Cullinan Therapeutics (NASDAQ:CGEM) issued its quarterly earnings data on Tuesday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.03, FiscalAI reports.

Here are the key takeaways from Cullinan Therapeutics’ conference call:

• CLN-978 (CD19xCD3) is positioned as a potential best-in-class subcutaneous T‑cell engager for autoimmune diseases with company‑sponsored data readouts scheduled in Q2 (SLE, RA), Q3 (multi‑dose RA) and Q4 (Sjögren’s) 2026.
• CLN-049 (FLT3xCD3) showed compelling monotherapy efficacy at ASH, earned FDA Fast Track designation, and the company plans to pick a recommended phase II dose this year and start a pivotal r/r study while initiating a frontline venetoclax combination by year‑end.
• The company completed an NDA submission for zipalertinib, and partner Taiho has finished frontline enrollment with top‑line data expected by year‑end, representing near‑term regulatory/commercial catalysts.
• Cullinan reported >$430 million in cash at year‑end, which management says provides runway into 2029 to fund advancement of CLN‑978, CLN‑049 and other programs.
• Key risks remain: early efficacy datasets are small (e.g., three NHL patients in FIH CLN‑978 work), CRS/ICANS risk requires step‑up dosing and inpatient monitoring initially, and durability/optimal dosing are still unresolved and could affect timelines or labeling.

Cullinan Therapeutics Stock Down 4.0%

Shares of NASDAQ CGEM opened at $14.31 on Thursday. The firm has a market cap of $845.38 million, a PE ratio of -4.27 and a beta of -0.15. The company’s fifty day simple moving average is $12.56 and its 200 day simple moving average is $9.86. Cullinan Therapeutics has a 12-month low of $5.68 and a 12-month high of $16.74.

Insider Transactions at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $15.68, for a total transaction of $125,440.00. Following the transaction, the insider owned 170,844 shares in the company, valued at approximately $2,678,833.92. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Nadim Ahmed sold 13,515 shares of the stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $14.47, for a total transaction of $195,562.05. Following the transaction, the chief executive officer directly owned 390,803 shares in the company, valued at $5,654,919.41. This trade represents a 3.34% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 107,912 shares of company stock valued at $1,420,241. 7.16% of the stock is owned by insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Cullinan Therapeutics by 62.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after purchasing an additional 1,036 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock worth $62,000 after buying an additional 2,523 shares during the last quarter. Quarry LP bought a new position in shares of Cullinan Therapeutics in the fourth quarter valued at $99,000. Great Lakes Advisors LLC bought a new position in shares of Cullinan Therapeutics in the fourth quarter valued at $128,000. Finally, Massar Capital Management LP acquired a new position in shares of Cullinan Therapeutics during the second quarter valued at about $101,000. Institutional investors own 86.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CGEM. HC Wainwright increased their target price on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a research note on Thursday, November 20th. Morgan Stanley reaffirmed an “overweight” rating and set a $30.00 price target on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cullinan Therapeutics in a report on Monday, December 29th. Finally, Wedbush lifted their price objective on Cullinan Therapeutics from $34.00 to $36.00 and gave the stock an “outperform” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.56.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.